Is low‑dose naltrexone (LDN) an appropriate treatment for Hashimoto’s thyroiditis, and what dosing regimen should be used?

Low-Dose Naltrexone for Hashimoto's Thyroiditis

Low-dose naltrexone (LDN) is not recommended for the treatment of Hashimoto's thyroiditis, as it lacks FDA approval for this indication, is not supported by established clinical practice guidelines, and has failed to demonstrate efficacy in controlled studies.

Evidence Against LDN Use

The most definitive evidence comes from a 2020 quasi-experimental study of 898 patients with hypothyroidism who started LDN 1. This study found no association between starting LDN and subsequent changes in thyroid hormone requirements—in fact, there was a tendency toward increasing levothyroxine consumption with greater LDN exposure. The authors explicitly concluded that their results "do not support claims of efficacy of LDN in hypothyroidism" 1.

A comprehensive 2026 narrative review examining LDN across multiple conditions reinforces this finding 2. The review analyzed 105 studies including 15 randomized controlled trials and concluded that early positive findings from uncontrolled studies were rarely replicated in placebo-controlled trials. The evidence base consists primarily of case reports and small feasibility studies prone to publication bias and relying on subjective outcomes 2.

FDA-Approved Indications

The FDA label for naltrexone specifies only two approved indications: treatment of alcoholism (50 mg daily) and opioid dependence (25-50 mg daily) 3. There is no FDA approval for low-dose naltrexone in any autoimmune condition, including Hashimoto's thyroiditis.

Guideline-Based Standard of Care

Established clinical practice guidelines from the American Association of Clinical Endocrinologists and American Thyroid Association make no mention of LDN as a treatment option for Hashimoto's thyroiditis 4. The standard of care remains:

• Levothyroxine replacement therapy for patients with overt hypothyroidism or TSH >10 mIU/L 5
• Dosing based on 1.6 µg/kg ideal body weight for athyreotic patients 4
• TSH monitoring at 4-8 weeks after initiation or dose changes 4
• Target TSH within the normal reference range (typically 0.45-4.12 mIU/L) 4

Clinical Context

While a 2026 narrative review mentions LDN among emerging adjunctive strategies for HT 6, it explicitly states that "current data are insufficient to support definitive clinical recommendations" and calls for high-quality randomized controlled trials. Another 2026 review on HT management does not include LDN among evidence-based treatment approaches 7.

The 2026 clinical review on LDN notes it is "generally safe, inexpensive and well tolerated" at 4.5 mg daily 2, but emphasizes that current evidence does not support routine clinical use. The review suggests LDN might have a pragmatic role only in treatment-resistant cases where standard therapies have failed, provided its experimental status and uncertain efficacy are clearly explained to patients 2.

Common Pitfalls to Avoid

• Do not prescribe LDN as first-line or adjunctive therapy for Hashimoto's thyroiditis based on anecdotal reports or patient requests
• Do not delay or substitute levothyroxine replacement with LDN in patients requiring thyroid hormone therapy
• Be aware that LDN requires compounding pharmacy preparation, which may pose access barriers and quality control concerns 8
• If patients are already taking LDN, monitor thyroid function regularly as there is no evidence it reduces levothyroxine requirements 1

When Patients Request LDN

If confronted with patient interest in LDN:

1. Explain the lack of evidence: Share that controlled studies show no benefit for thyroid function or hormone requirements
2. Optimize standard therapy first: Ensure adequate levothyroxine dosing with TSH in target range
3. Address persistent symptoms: If symptoms persist despite biochemical euthyroidism, consider other evidence-based approaches (selenium supplementation has more supportive data for reducing anti-TPO antibodies and improving well-being in some studies 4)
4. Document informed consent: If proceeding with LDN in treatment-refractory cases, clearly document its experimental nature and lack of proven efficacy

The evidence-based approach to Hashimoto's thyroiditis remains levothyroxine replacement therapy guided by TSH monitoring, as outlined in established clinical practice guidelines 5, 4.